Three new Article 13 omega-3 claims approved

The European Parliament demonstrates their continued support to EPA/DHA Omega-3 as a vital nutrient by approving three new Article 13 omega-3 claims:

- DHA contributes to the maintenance of normal blood triglyceride levels
- DHA and EPA contribute to the maintenance of normal blood pressure
- DHA and EPA contribute to the maintenance of normal blood triglyceride concentrations

These are all high dosage claims; between 2-3 grams of EPA/DHA – easily reached with Epax’ premium quality highly concentrated Omega-3 oils.

“We are very excited to start working with new business opportunities in Europe with these ground-breaking new claims, which, no doubt, will give the already successful Omega-3 category yet another massive boost,” states Thomas Gulbrandsen, executive vice president, Sales and Marketing Nutra at Epax.  

The claims will come into effect in December 2013.

Based in Oslo in Norway, Epax is a leading manufacturer of high-quality concentrated marine EPA/DHA omega-3 oils in the nutraceutical business-to-business segment under the brand name EPAX?. The products are available in a wide range of top-quality formulas with different EPA/DHA ratios and concentrations that are focused on specific health conditions. Products are available in TG, TGN and EE versions and the product range is backed by clinical studies. The manufacturing facility is GMP certified by the Norwegian Medicines Agency and HACCP approved by the Norwegian Food Safety AuthorityAir Jordan IV 4 Retro Denim